Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy

OBJECTIVE: Nearly 5% of patients with breast cancer carry germline BRCA mutations, which are more common in triple-negative breast cancer (TNBC). Previous clinical trials demonstrated the therapeutic efficacy of poly (ADP-ribose) polymerase inhibitors (PARPis) against BRCA-mutated metastatic breast...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Int Med Res
Asıl Yazarlar: Chen, Zheling, Wang, Xiao, Li, Xiao, Zhou, Yucheng, Chen, Ke
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SAGE Publications 2021
Konular:
Systematic Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8164563/
https://ncbi.nlm.nih.gov/pubmed/33541181
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0300060521991019
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller